344 related articles for article (PubMed ID: 15466983)
1. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.
Mantovani G; Madeddu C; Macciò A; Gramignano G; Lusso MR; Massa E; Astara G; Serpe R
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1651-9. PubMed ID: 15466983
[TBL] [Abstract][Full Text] [Related]
2. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Lusso MR; Serpe R; Massa E; Astara G; Deiana L
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1030-4. PubMed ID: 16702388
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C
Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.
Gramignano G; Lusso MR; Madeddu C; Massa E; Serpe R; Deiana L; Lamonica G; Dessì M; Spiga C; Astara G; Macciò A; Mantovani G
Nutrition; 2006 Feb; 22(2):136-45. PubMed ID: 16459226
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.
Macciò A; Madeddu C; Gramignano G; Mulas C; Floris C; Sanna E; Cau MC; Panzone F; Mantovani G
Gynecol Oncol; 2012 Mar; 124(3):417-25. PubMed ID: 22198049
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.
Madeddu C; Dessì M; Panzone F; Serpe R; Antoni G; Cau MC; Montaldo L; Mela Q; Mura M; Astara G; Tanca FM; Macciò A; Mantovani G
Clin Nutr; 2012 Apr; 31(2):176-82. PubMed ID: 22047681
[TBL] [Abstract][Full Text] [Related]
7. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Cerchietti LC; Navigante AH; Castro MA
Nutr Cancer; 2007; 59(1):14-20. PubMed ID: 17927497
[TBL] [Abstract][Full Text] [Related]
8. Cancer-related cachexia and oxidative stress: beyond current therapeutic options.
Mantovani G; Macciò A; Madeddu C; Massa E
Expert Rev Anticancer Ther; 2003 Jun; 3(3):381-92. PubMed ID: 12820780
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Mantovani G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):292-301. PubMed ID: 20496538
[TBL] [Abstract][Full Text] [Related]
11. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients.
Fortunati N; Manti R; Birocco N; Pugliese M; Brignardello E; Ciuffreda L; Catalano MG; Aragno M; Boccuzzi G
Oncol Rep; 2007 Dec; 18(6):1521-7. PubMed ID: 17982639
[TBL] [Abstract][Full Text] [Related]
12. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and wasting in cancer.
Laviano A; Meguid MM; Preziosa I; Rossi Fanelli F
Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):449-56. PubMed ID: 17563463
[TBL] [Abstract][Full Text] [Related]
14. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Semin Oncol; 1998 Apr; 25(2 Suppl 6):45-52. PubMed ID: 9625383
[TBL] [Abstract][Full Text] [Related]
15. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.
Tomíska M; Tomisková M; Salajka F; Adam Z; Vorlícek J
Neoplasma; 2003; 50(3):227-33. PubMed ID: 12937858
[TBL] [Abstract][Full Text] [Related]
16. [Recent development in research and management of cancer anorexia-cachexia syndrome].
Inui A
Gan To Kagaku Ryoho; 2005 Jun; 32(6):743-9. PubMed ID: 15984510
[TBL] [Abstract][Full Text] [Related]
17. Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself.
Laviano A; Meguid MM; Inui A; Muscaritoli M; Rossi-Fanelli F
Nat Clin Pract Oncol; 2005 Mar; 2(3):158-65. PubMed ID: 16264909
[TBL] [Abstract][Full Text] [Related]
18. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Wen HS; Li X; Cao YZ; Zhang CC; Yang F; Shi YM; Peng LM
Chemotherapy; 2012; 58(6):461-7. PubMed ID: 23406994
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment.
Mantovani G; Macciò A; Madeddu C; Mura L; Massa E; Gramignano G; Lusso MR; Murgia V; Camboni P; Ferreli L
J Environ Pathol Toxicol Oncol; 2003; 22(1):17-28. PubMed ID: 12678402
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.
Mantovani G; Macciò A; Madeddu C; Mura L; Gramignano G; Lusso MR; Massa E; Mocci M; Serpe R
J Mol Med (Berl); 2003 Oct; 81(10):664-73. PubMed ID: 12928788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
